20.6 Malaria: Species, Life Cycle & Severe Disease

Returning travellers presenting with acute febrile illnesses represent a high-stakes, time-critical domain in the MRCP(UK) Part 1 examination. Candidates must immediately recognize the laboratory and clinical hallmarks of severe Plasmodium falciparum malaria, differentiate malarial species, manage relapsing hypnozoite infections safely, identify enteric fever, diagnose arboviral and zoonotic fevers (dengue, leptospirosis), and delineate parasitic tissue infections (amoebic liver abscess and schistosomiasis).

1. Malaria: Species Biology, Life Cycle & Clinical Hallmarks

Malaria is transmitted via the nocturnal bite of an infected female Anopheles mosquito, which inoculates motile sporozoites into the human bloodstream. Sporozoites rapidly migrate to the liver, invading hepatocytes within 30 to 60 minutes to initiate asymptomatic asexual liver-stage development (exo-erythrocytic schizogony). After 5 to 16 days, infected hepatocytes rupture, releasing thousands of merozoites into the circulation to invade host erythrocytes, initiating cyclic erythrocytic schizogony.

Comparison of Human Plasmodium Species

Molecular Pathogenesis of Severe Falciparum Malaria

P. falciparum is uniquely lethal among human malaria species because of microvascular sequestration. As intra-erythrocytic trophozoites mature, the parasite synthesizes and exports Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) to the host red cell surface, where it aggregates into electron-dense 'knobs'. PfEMP-1 acts as a high-affinity ligand that binds endothelial host receptors:

• CD36 (on microvascular endothelium)
• Intercellular Adhesion Molecule 1 (ICAM-1) (on cerebral microvascular endothelium)
• Endothelial Protein C Receptor (EPCR) (disrupts vascular barrier integrity and activates coagulation)
• Chondroitin Sulfate A (CSA) (on placental syncytiotrophoblast; placental malaria)

Sequestration of rigid, parasitized erythrocytes causes profound microvascular obstruction, capillary occlusion, localized endothelial ischaemia, and intense tissue dysoxia. In the cerebral microcirculation, this causes diffuse cerebral oedema, breakdown of the blood-brain barrier, and intracranial hypertension (cerebral malaria). Crucially, because late trophozoites and schizonts are sequestered in deep capillary beds, peripheral blood smears reflect only circulating young ring forms, occasionally underestimating the true systemic parasite burden.

2. Severe Falciparum Malaria vs. Uncomplicated Malaria

Consensus Criteria for Severe Falciparum Malaria (WHO & UK Guidelines)

Severe malaria is defined by the presence of asexual P. falciparum parasitaemia alongside one or more of the following clinical or laboratory severity criteria:

1. High Parasitaemia: $> 10%$ of circulating red cells parasitized in any patient, OR $> 2%$ in non-immune individuals.
2. Impaired Consciousness / Cerebral Malaria: Glasgow Coma Scale (GCS) score $< 11$ in adults (or Blantyre Coma Score $< 3$ in children).
3. Severe Metabolic Acidosis: Standard base deficit $> 8\text{ mmol/L}$, arterial $\text{pH} < 7.30$, plasma bicarbonate $< 15\text{ mmol/L}$, or venous blood lactate $\ge 5.0\text{ mmol/L}$ (the strongest independent predictor of death).
4. Severe Normocytic Anaemia: Haemoglobin $< 70\text{ g/L}$ ($< 7\text{ g/dL}$) or haematocrit $< 20%$.
5. Acute Kidney Injury: Serum creatinine $> 265\ \mu\text{mol/L}$ ($> 3.0\text{ mg/dL}$) or blood urea $> 20\text{ mmol/L}$, or oliguria ($< 0.5\text{ mL/kg/h}$). Oliguric renal failure is caused by acute tubular necrosis secondary to microvascular obstruction, haemolysis, and haemoglobinuria ('blackwater fever').
6. Pulmonary Oedema / ARDS: Non-cardiogenic pulmonary oedema with severe hypoxaemia ($\text{PaO}_2/\text{FiO}_2 < 300$).
7. Hypoglycaemia: Blood glucose $< 2.2\text{ mmol/L}$ ($< 40\text{ mg/dL}$) (exacerbated by parasite glucose consumption and historically worsened by quinine-induced pancreatic beta-cell insulin secretion).
8. Circulatory Collapse / Algid Malaria: Systolic blood pressure $< 90\text{ mmHg}$ with core-to-skin temperature gradient and cool peripheries.
9. Spontaneous Bleeding / Disseminated Intravascular Coagulation (DIC): Clinically apparent bleeding from venepuncture sites or gastrointestinal tract, with thrombocytopenia and prolonged prothrombin time.
10. Macroscopic Haemoglobinuria: Dark black/burgundy urine ('blackwater fever') reflecting massive intravascular haemolysis.
11. Jaundice: Total serum bilirubin $> 50\ \mu\text{mol/L}$ ($> 3.0\text{ mg/dL}$) with concurrent evidence of other organ dysfunction.

Evidence-Based Treatment Protocols

[Confirmed Malaria Diagnosis]
       │
       ├─► [Severe Malaria Criteria Present?]
       │         │
       │         ├─► YES: Immediate IV Artesunate 2.4 mg/kg at 0, 12, 24h
       │         │        (Minimum 24h IV therapy until tolerating oral ACT)
       │         │
       │         └─► NO: Uncomplicated Malaria
       │
       └─► [Species Identification]
                 │
                 ├─► P. falciparum: Oral ACT (Artemether-lumefantrine [Riamet]
                 │                  or Dihydroartemisinin-piperaquine)
                 │
                 └─► P. vivax / P. ovale: Oral Chloroquine or ACT
                                          PLUS Mandatory G6PD Screening
                                          ──► If G6PD Normal: Oral Primaquine
                                              (14 days for hypnozoite cure)

• First-Line Therapy for Severe Malaria: Intravenous Artesunate ($2.4\text{ mg/kg}$ IV administered at 0, 12, and 24 hours, then once daily).
  • Evidence: Landmark multicentre randomized trials (SEAQUAMAT in Asia and AQUAMAT in Africa) demonstrated that intravenous artesunate confers a $35%$ relative reduction in mortality compared to intravenous quinine. Artesunate acts significantly faster, clears ring-stage parasites before sequestration occurs, and does not induce hyperinsulinaemic hypoglycaemia or cardiac arrhythmias (QTc prolongation), which plague quinine therapy.
  • Duration: Intravenous artesunate must be administered for a minimum of 24 hours (at least 3 full doses), even if the patient can swallow earlier. Once 24 hours of IV therapy are completed and the patient can tolerate oral intake, switch to a complete 3-day course of an oral Artemisinin-based Combination Therapy (ACT).
• First-Line Therapy for Uncomplicated P. falciparum Malaria: Oral Artemisinin-based Combination Therapy (ACT):
  • Artemether with lumefantrine (Riamet: fixed-dose 6-dose regimen taken over 60 hours with fatty food), OR
  • Dihydroartemisinin-piperaquine (Eurartesim: once-daily dosing for 3 days).
• Radical Hypnozoite Cure for P. vivax & P. ovale (Primaquine Protocol):
  • Blood-stage schizonts are cleared with oral chloroquine or ACT.
  • To eradicate dormant liver hypnozoites and prevent late relapse, oral primaquine ($0.5\text{ mg/kg/day}$ for 14 days) must be administered.
  • MANDATORY PRE-TREATMENT G6PD SCREENING: Primaquine is a potent 8-aminoquinoline oxidant. In individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, primaquine triggers catastrophic acute intravascular haemolysis with haemoglobinuria and acute renal failure. Quantitative G6PD enzyme testing must be confirmed normal prior to the first dose of primaquine.